Replies to post #42006 on Relief Therapeutics Holding AG (RLFTF)

[PennyWorld]

This study is assumed to be 100% financed by RLFTF, so I'm reasonably sure that RAM would not be initiating and carrying out that study for just 2.5% of profits. I suspect that the collab agreement does not cover the derivatives from this trial. That would be a great question for RLFTF!!

---------------
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

https://finance.yahoo.com/news/relief-points-applied-pharma-research-052000691.html

GENEVA, SWITZERLAND / ACCESSWIRE / May 17, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent announcement by APR Applied Pharma Research S.A. ("APR") regarding the initiation of a pivotal clinical trial with its novel nasal spray, temporarily codenamed APR-AOS2020, a Class III medical device, in patients with mild COVID-19. The trial is designed to evaluate the efficacy and safety of the product in reducing viral load in the upper respiratory airways in recently infected individuals.